Humanized antihuman IL-6 receptor antibody, tocilizumab

Handbook of Experimental Pharmacology

Volumn 181, Issue , 2008, Pages 151-160

  Nishimoto, N ^a   Kishimoto, T ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; ATLIZUMAB; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; HUMAN; IMMUNOLOGY; METABOLISM; PROTEIN CONFORMATION; PROTEIN ENGINEERING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN-6; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 38449084902     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-540-73259-4_7     Document Type: Article

References (16)

1. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, Feldmann M, Maini RN (1999) Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163:1521-1528
2. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panay GS (2002) Therapeutic benefit after blocking interleukin-6 activity in rheumatoid arthritis with an anti-interleukin-6 receptor monoclonal antibody. Arthritis Rheum 46:3143-3150
3. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A,Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohns disease. Gastroenterol 126:989-996
4. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T CHARISMA Study Group (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817-2829
5. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 5:1731-1740
6. Nishimoto N, Ogata A, Shima Y, Tani Y, Ogawa H, Nakagawa M, Sugiyama H, Yoshizaki K, Kishimoto T (1994) Oncostatin M, leukemia inhibitory factor, and interleukin-6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J Exp Med 179:1343-1347
7. Nishimoto N, Yoshizaki K,Maeda K, Kuritani T, Deguchi H, Sato B, Imai N, Suemura M, Kakei T, Takagi N, Kishimoto T (2003) Toxicity, Pharmacokinetics, and Dose-Finding Study of Repetitive Treatment with the Humanized Anti-Interleukin 6 Receptor AntibodyMRA in Rheumatoid Arthritis. Phase I/II Clinical Study. J Rheumatol 30:1426-1435
8. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T (2004) Treatment of rheumatoid arthritis with humanized antiinterleukin 6 receptor antibody. Arthritis Rheum 50:1761-1769
9. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, HaraM, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castlemans disease. Blood 106:2627-2632
10. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66:1162-1167
11. Nishimoto N (2006) Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol 18:277-281
12. Ogawa J, Harigai M, Akashi T, Nagasaka K, Suzuki F, Tominaga S, Miyasaka N (2006) Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody. Ann Rheum Dis 65:1667-1669
13. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM (1993) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 53:851-856
14. Scheller J, Ohnesorge N, Rose-John S (2006) Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 63:321-329
15. Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M (2006) Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 1069:414-419
16. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, Nishimoto N, Yoshizaki K, Kishimoto T (2005) Therapeutic efficacy of humanized recombinant anti-IL 6-receptor antibody for children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52:818-825